Investors See European Pharma Stocks as Funding Source for AI Trades
Dow Jones06-30
1251 GMT - Investors are souring on European pharmaceutical and biotech stocks, UBS analysts say in a research note. "Overall, sentiment is relatively negative for European pharma and biotech sector, and many investors see the sector as a source of funding for AI trades," the analysts say. There is interest in biotech, which can generate outsized returns if the right call is made at the right time, they add. Among European midsized pharma and biotech companies, Argenx, Genmab, Ipsen and UCB attract high investor interest, according to UBS. The Stoxx Europe 600 Health Care index rises 0.8%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 30, 2026 08:52 ET (12:52 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments